Close Menu

Precision Oncology News: Breaking News

Carebox's system matches eligibility criteria from clinical trial databases with patients' health and genomic data to identify potentially relevant studies.

PanCAN has partnered with Tempus to provide panel genomic testing for every patient enrolled in the Precision Promise platform study.

Patients in the Phase II trial will receive infusions of autologous T cells that have been genetically engineered to remove the intracellular checkpoint CISH.

The companies will combine Neogene's expertise in targeting tumor neoantigens with Twist's DNA synthesis platform and product lines.

The data are from two clinical trials and an expanded access program evaluating derazantinib in certain patients with intrahepatic cholangiocarcinoma.

Yourgene will provide its Elucigene DPYD tests to screen approximately 200 patients each month for the next year.

The drug, LP-184, demonstrated increased efficacy against prostate cancer cells overexpressing PTGR1 in preclinical studies and inspired further research.

The Phase I/II trial will assess the safety, recommended dose, initial efficacy, and pharmacokinetics of the autologous T-cell therapy ET140203 Artemis.

An Invitae-led retrospective study found almost a third of cancer patients who underwent germline genetic testing after tumor sequencing had pathogenic variants.

Investigators are conducting a prospectively designed, retrospective study of archived material from the NeoTRIPaPDL1 triple negative breast cancer trial.

With the FDA's acceptance of its IND application for the drug, the Boston-headquartered firm will begin studying it in TP53-mutated MDS patients.

The company will use the funds to advance clinical development of its T-cell module platform and in-house manufacturing of three cell-based treatments.

Published data from the ExteNET trial show an overall survival benefit with Nerlynx versus placebo in HER2-positive disease after treatment with Herceptin.

The firm will conduct genomic and transcriptomic analysis to identify predictors of response to the personalized immunotherapy TG4050.

The company said data from the Phase II portion of the CodeBreak-100 study in KRAS-mutated lung cancer patients was positive and may be registrational.

The researchers used tumor and germline whole-genome sequencing, RNA sequencing, and methylome analysis to elucidate the molecular basis of high-risk cancers.

Based on the study results, the score could be combined with other risk factors to improve predictions of contralateral breast cancer and stratify patients.

Using baseline blood samples, researchers have identified an eight-gene expression signature to predict patient responses to Zytiga plus prednisone or Xtandi.

Besides speeding up and increasing enrollment, the Guardant360 test identified a greater number of actionable mutations than tissue-based genotyping.

The merger brings tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings.

The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.

The Norwegian company will receive $200 million upfront from Genentech for the rights to its investigational neoantigen-based cancer vaccine, VB10.NEO.

The Phase I/II trial will assess the safety and efficacy of the CAR T cell therapy MB-102 for patients with three types of hematologic malignancies.

The study, supported by TargetCancer, Foundation Medicine, and Bayer, aims to match 400 patients with rare cancers to personalized treatments based on NGS.

Sermonix will launch the ELAINE-1 study at Exactis Innovation network sites across Canada to study the activity of its drug in ESR1-mutated breast cancer.